Intrathecal drug delivery (IDD) is an innovative approach for managing pain, particularly in patients suffering from cancer-related pain or chronic pain conditions. This method involves delivering ...

allowing healthcare providers to adjust medication delivery rates according to the patient's specific needs. Enhanced programmability and longer battery lives improve both the efficacy and convenience ...

The blood–brain barrier is the biggest challenge to the development of drugs that target the CNS. Most capillary beds leak plasma contents between and across endothelial cells by way of window-like ...

Trial registration International Standard Randomised Controlled Trials Centre (ISRCTN 33733462). Recent systematic reviews were unable to find randomised controlled trials evaluating the effectiveness ...

That's important, as Zolgensma is the world's most expensive drug, costing more than $2.1 million for a one-shot dose. Intrathecal delivery could kickstart sales of Zolgensma, which have taken a ...

Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic ...

Novartis plans to share results with regulatory agencies in 2025, including the US Food and Drug Administration (FDA), with the aim to make OAV101 IT ... Novartis has an exclusive, worldwide license ...

Intrathecal anesthesia is commonly associated with nausea post delivery; [1,2,3 ... A known adverse effect of metronidazole (Flagyl) is a drug-drug reaction that occurs when metronidazole and ...

Novartis has reported positive phase 3 results with intrathecal dosing of its spinal muscular atrophy (SMA) gene therapy Zolgensma, which could extend the range of children eligible for the drug.

Novartis said it plans to share the Steer results with regulators, including the FDA, to seek approvals for OAV-101 IT. Grant said a submission is expected in the first half of 2025. Novartis had ...

Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, ...

intending to bring to market an innovative targeted drug delivery system that uses – you guessed it – milk. The pair have committed to using their milk-based tech to treat both common and rare ...